Sernova (TSE:SVA) has released an update.
Sernova Corp., a clinical-stage biotech company, has announced the appointment of Jonathan Rigby to its Board of Directors. Rigby, with over three decades of biopharmaceutical experience and a personal connection to Type 1 diabetes, brings a wealth of industry knowledge from his previous leadership roles and board positions. His addition is expected to significantly contribute to Sernova’s mission to develop cell therapy treatments for chronic diseases, including a ‘functional cure’ for Type 1 diabetes.
For further insights into TSE:SVA stock, check out TipRanks’ Stock Analysis page.
